利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

56 条记录 (耗时 0.035 秒)

    METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA
    4.
    发明申请
    METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA 审中-公开
    用于治疗糖尿病和DYSLIPIDEMIA的方法和组合物

    公开(公告)号：US20140121267A1

    公开(公告)日：2014-05-01

    申请号：US14148572

    申请日：2014-01-06

    申请人： Ish Khanna ,  Sivaram Pillarisetti

    发明人： Ish Khanna ,  Sivaram Pillarisetti

    IPC分类号： C07C311/51

    CPC分类号： C07C311/51 ,  A61K31/18 ,  A61K31/255 ,  C07C2601/02 ,  C07D257/04

    摘要： Novel compounds of Formula A1 are provided: its stereoisomers and/or pharmaceutically acceptable salts for the treatment of diabetes and diabetes-associated dyslipidemia, wherein R7 is independently selected from a group consisting of hydroxy, alkoxy, alkyl, amine, NHR′ wherein R′ is alkyl or cycloalkyl optionally substituted by hydroxy or alkoxy, NHSO2R or NHCOR, wherein R is selected from alkyl or cycloalkyl. At least one of R3 and R4 and/or R5 and R6 form a cyclic ring of 3-8 carbon atoms optionally containing alkyl groups, hetero atoms, or functional groups such as O, N, SO2. Additionally R3 and R4 or R5 and R6, when they do not form a cyclic ring, are independently selected from hydrogen, alkyl, branched alkyl, and cycloalkyl. L1 is independently a linear aliphatic chain optionally containing from 6 to 16 carbon-atoms and L1 may optionally be substituted one or more times by alkyl, branched alkyl, cycloalkyl, or aryl.

    摘要翻译： 提供式A1的新型化合物：其用于治疗糖尿病和糖尿病相关血脂异常的其立体异构体和/或药学上可接受的盐，其中R 7独立地选自羟基，烷氧基，烷基，胺，NHR'，其中R' 是任选被羟基或烷氧基取代的烷基或环烷基，NHSO 2 R或NHCOR，其中R选自烷基或环烷基。 R3和R4和/或R5和R6中的至少一个形成任选含有烷基，杂原子或官能团如O，N，SO 2的3-8个碳原子的环。 另外，当它们不形成环时，R 3和R 4或R 5和R 6独立地选自氢，烷基，支链烷基和环烷基。 L1独立地是任选含有6至16个碳原子的直链脂族链，并且L 1可以任选被烷基，支链烷基，环烷基或芳基取代一次或多次。

    Methods and Compositions for Upregulation of GATA Activity
    7.
    发明申请
    Methods and Compositions for Upregulation of GATA Activity 审中-公开
    用于上调GATA活性的方法和组成

    公开(公告)号：US20080275049A1

    公开(公告)日：2008-11-06

    申请号：US12113426

    申请日：2008-05-01

    申请人： John Anastasios Polikandriotis ,  Sivaram Pillarisetti ,  Ish Khanna ,  Uday Saxena

    发明人： John Anastasios Polikandriotis ,  Sivaram Pillarisetti ,  Ish Khanna ,  Uday Saxena

    IPC分类号： A61K31/53 ,  C12Q1/02 ,  A61P9/10 ,  C12Q1/66

    CPC分类号： G01N33/5067 ,  A61K31/53 ,  G01N2333/4703

    摘要： A novel method of identifying compounds capable of upregulating GATA activity is disclosed. The method includes providing a sample of cells that express GATA, providing a sample of a candidate compound, contacting the cell sample and the compound sample, and measuring a quantitative indicator of GATA activity within the cell sample after the contacting step. GATA inducers identified by the method and uses therefore to upregulate GATA activity in subjects and to prevent or treat atherosclerosis or diabetes in subjects are also described.

    摘要翻译： 公开了鉴定能够上调GATA活性的化合物的新方法。 该方法包括提供表达GATA的细胞样品，提供候选化合物样品，接触细胞样品和化合物样品，以及在接触步骤之后测量细胞样品内GATA活性的定量指标。 还描述了通过该方法鉴定的GATA诱导物并因此用于上调受试者中的GATA活性并预防或治疗受试者的动脉粥样硬化或糖尿病。

    METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA
    10.
    发明申请
    METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA 审中-公开
    用于治疗糖尿病和DYSLIPIDEMIA的方法和组合物

    公开(公告)号：US20140142178A1

    公开(公告)日：2014-05-22

    申请号：US14148580

    申请日：2014-01-06

    申请人： Ish Khanna ,  Sivaram Pillarisetti

    发明人： Ish Khanna ,  Sivaram Pillarisetti

    IPC分类号： C07C311/51

    CPC分类号： C07C311/51 ,  C07C31/27 ,  C07C43/115 ,  C07C53/132 ,  C07C61/12 ,  C07C61/15 ,  C07C69/608 ,  C07C69/74 ,  C07C233/58 ,  C07C233/60 ,  C07C255/46 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07D257/04

    摘要： Novel compounds of Formula I are provided: its stereoisomers and/or pharmaceutically acceptable salts for the treatment of diabetes and diabetes-associated dyslipidemia, wherein R1 is selected from a group consisting of hydroxy, alkoxy, amine, alkyl, haloalkyl, NHSO2R, or NHCOR wherein R is selected from alkyl or cycloalkyl, NHR′ wherein R′ is alkyl or cycloalkyl optionally substituted by hydroxy or alkoxy; and n1 and n2 are independently selected from 0, 1, and 2. At least one of R3 and R4 and/or R5 and R6 form a cyclic ring of 3-8 carbon atoms optionally containing alkyl groups, hetero atoms, or functional groups such as O, N, SO2. Additionally, when R3 and R4 or R5 and R6 do not form a cyclic ring, then they may be independently selected from hydrogen, alkyl, branched alkyl, and cycloalkyl. L1 is a linear aliphatic chain optionally containing from 4 to 16 carbon atoms. The chain may optionally be substituted one or more times by alkyl, branched alkyl, cycloalkyl, or aryl. R2 is independently selected from hydrogen, alkoxy, hydroxy, alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, cyano, or COR7, wherein R7 is selected from hydroxy, alkyl, alkoxy, or amine, NHR′, NHSO2R, or NHCOR. Y1 is oxygen or hydrogen. Y2 is optional, wherein when Y2 is present, Y1 and Y2 are hydrogen. When Y2 is not present, Y1 is a carbonyl group.

    摘要翻译： 提供式I的新型化合物：其用于治疗糖尿病和糖尿病相关血脂异常的其立体异构体和/或药学上可接受的盐，其中R 1选自羟基，烷氧基，胺，烷基，卤代烷基，NHSO 2 R或NHCOR 其中R选自烷基或环烷基，NHR'，其中R'是任选被羟基或烷氧基取代的烷基或环烷基; 并且n1和n2独立地选自0,1和2. R3和R4和/或R5和R6中的至少一个形成3-8个碳原子的环状环，任选地含有烷基，杂原子或官能团，例如 作为O，N，SO 2。 此外，当R3和R4或R5和R6不形成环时，它们可以独立地选自氢，烷基，支链烷基和环烷基。 L1是任选含有4至16个碳原子的直链脂族链。 该链可以任选地被烷基，支链烷基，环烷基或芳基取代一次或多次。 R 2独立地选自氢，烷氧基，羟基，烷基，卤代烷基，环烷基，杂环烷基，杂芳基，氰基或COR 7，其中R 7选自羟基，烷基，烷氧基或胺，NHR'，NHSO 2 R或NHCOR。 Y1是氧或氢。 Y2是任选的，其中当存在Y2时，Y1和Y2是氢。 当不存在Y2时，Y1是羰基。